Iodine-125 episcleral plaque therapy in uveal melanoma

2000 ◽  
Vol 28 (6) ◽  
pp. 409-413 ◽  
Author(s):  
Serena Sia ◽  
Chris Harper ◽  
Ian McAllister ◽  
Adrian Perry
Keyword(s):  
Uveal Melanoma ◽  
Iodine 125

A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma

2015 ◽  
Vol 5 (3) ◽  
pp. e169-e176 ◽  
Author(s):  
Vinita Takiar ◽  
K. Ranh Voong ◽  
Dan S. Gombos ◽  
Firas Mourtada ◽  
Laura A. Rechner ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Definitive Treatment ◽  
Iodine 125

Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma

2020 ◽  
Vol 29 (1) ◽  
pp. 1-10
Author(s):  
Eun-Ah Kim ◽  
Diana Salazar ◽  
Colin A. McCannel ◽  
Mitchell Kamrava ◽  
David J. Demanes ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Iodine 125

Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma

Ophthalmology ◽  
2017 ◽  
Vol 124 (10) ◽  
pp. 1532-1539 ◽  
Author(s):  
Prithvi Mruthyunjaya ◽  
Michael I. Seider ◽  
Sandra Stinnett ◽  
Amy Schefler ◽  
Prithvi Mruthyunjaya ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gene Expression Profile ◽  
Uveal Melanoma ◽  
Expression Profile ◽  
Tumor Regression ◽  
Regression Rate ◽  
Plaque Radiotherapy ◽  
Iodine 125

Iodine-125 Radiation of Posterior Uveal Melanoma

Ophthalmology ◽  
1987 ◽  
Vol 94 (12) ◽  
pp. 1621-1626 ◽  
Author(s):  
Samuel Packer
Keyword(s):  
Uveal Melanoma ◽  
Iodine 125

Ultrastructural Alterations in Extraocular Muscles Following Iodine-125 Brachytherapy for Uveal Melanoma

Strabismus ◽  
2007 ◽  
Vol 15 (2) ◽  
pp. 103-109 ◽  
Author(s):  
Hayyam Kïratlï ◽  
Pinar Topcu Yïlmaz ◽  
Mustafa Sargon
Keyword(s):  
Uveal Melanoma ◽  
Extraocular Muscles ◽  
Ultrastructural Alterations ◽  
Iodine 125

scholarly journals Conjunctival Dehiscence and Scleral Necrosis following Iodine-125 Plaque Brachytherapy for Uveal Melanoma: A Report of 3 Cases

2018 ◽  
Vol 4 (5) ◽  
pp. 291-296 ◽  
Author(s):  
Duncan E. Berry ◽  
Dilraj S. Grewal ◽  
Prithvi Mruthyunjaya
Keyword(s):  
Uveal Melanoma ◽  
Iodine 125 ◽  
Plaque Brachytherapy

Visual Outcomes and Eye Preservation After Iodine-125 Brachytherapy for Uveal Melanoma

2005 ◽  
Vol 63 ◽  
pp. S159
Author(s):  
A.F. Blurton ◽  
A. De La Garza ◽  
T. McCoy ◽  
K. Ekstrand ◽  
C. Greven ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Visual Outcomes ◽  
Iodine 125

Monthly Intravitreal Bevacizumab for Macular Edema after Iodine-125 Plaque Radiotherapy of Uveal Melanoma

2014 ◽  
Vol 24 (2) ◽  
pp. 228-234 ◽  
Author(s):  
Arman Mashayekhi ◽  
Duangnate Rojanaporn ◽  
Saad Al-Dahmash ◽  
Carol L. Shields ◽  
Jerry A. Shields
Keyword(s):  
Macular Edema ◽  
Uveal Melanoma ◽  
Intravitreal Bevacizumab ◽  
Plaque Radiotherapy ◽  
Iodine 125

scholarly journals No Gender Differences in Long-Term Survival after Brachytherapy of 1,541 Patients with Uveal Melanoma

2019 ◽  
Vol 5 (6) ◽  
pp. 432-439 ◽  
Author(s):  
Gustav Stålhammar ◽  
Thonnie Rose See ◽  
Maria Filì ◽  
Stefan Seregard
Keyword(s):  
Uveal Melanoma ◽  
Therapeutic Interventions ◽  
Term Survival ◽  
Men And Women ◽  
Kaplan Meier ◽  
Iodine 125 ◽  
Gender Based ◽  
Survival Differences ◽  
Related Mortality ◽  
Plaque Brachytherapy

Background: In several malignancies, gender-based survival differences after specific therapeutic interventions have been demonstrated. It is not known whether such differences exist after plaque brachytherapy of uveal melanoma. Methods: All patients who received brachytherapy for uveal melanoma at St. Erik Eye Hospital from November 1, 1979 through November 20, 2017 were included (n = 1,541). Retrospective data were retrieved including baseline patient and tumor characteristics, brachytherapy nuclide (ruthenium-106 or iodine-125), radiation dose, treatment duration, tumor relapses, date of metastasis, and cause of death. Results: A total of 775 men and 766 women were treated with plaque brachytherapy. There were no significant differences between the genders in baseline characteristics, treatment, or follow-up. Men and women had similar rates of tumor relapses, hazard for repeated brachytherapy (men vs. women 0.8, p = 0.47), enucleation-free survival, and survival after detection of metastasis. Five-, 10-, and 15-year melanoma-related mortality was 14, 24, and 27% for men and 15, 26, and 32% for women, respectively. There were no significant differences in hazard for melanoma-related mortality (men vs. women 0.9, p = 0.32), median Kaplan-Meier disease-specific survival (men 18.2 years, women 15.5 years, p = 0.22), or median overall survival (men 13.5 years, women 12.6 years, p = 0.60). Conclusion: There are no relevant differences between men and women in ocular or patient survival after brachytherapy for uveal melanoma.

Sign in / Sign up

Export Citation Format

Share Document